# Satoshi Trials in Action By [Canurta.eth](https://paragraph.com/@canurta) · 2025-07-23 --- _To the Canurta community & Bitcoin enthusiasts_ Today marks a defining moment in Canurta’s journey—our first Satoshi Trials™ loan, secured directly against our Bitcoin treasury, has closed. On May 13, 2025, we leveraged 0.34765 BTC as Collateral with APX Lending for a simple fixed-rate facility, showcasing our innovative R&D Strategy. These funds immediately kick-start our new R&D partnership with TransBioTech, where we’ll embark on a two-part preclinical program (toxicology and BBB penetration studies) for CNR-401, our lead adaptive-medicine candidate, for the treatment of ALS. Why does this matter? By pledging Bitcoin—rather than diluting equity or mortgaging physical assets—we’ve unlocked capital in a matter of days. The APX process was seamless: no lengthy covenants, no appraisal delays, no board sign-offs on heavy equipment—just a swift drawdown that puts cash in our account when and where R&D demands it. Compare that to a traditional equipment or real-estate loan: paperwork meanders for weeks, if not months; covenants drag you into endless negotiations; and interest rates are often higher. From here, our funding stack will blend: * **R&D tax credits** to reimburse eligible research spend, * **Shareholder support** via modest revenue‐share or royalty structures, and * **Bitcoin appreciation** as an offset to financing costs. Over the life of this loan, any appreciation in our BTC holdings directly reduces net borrowing costs—turning a liability into another potential value driver. More importantly, we’ll demonstrate that a Canadian biotech can sustainably leverage Bitcoin on its balance sheet to accelerate ALS research without excessive dilution and continued fundraising in dire funding climates. To our investors, this transaction signals that Canurta is not just innovating in the lab, but innovating in finance. We’re building a blueprint where cutting-edge adaptive medicine is underwritten by best-in-class treasury management—bridging digital-asset finance with life-science impact. This is exactly the kind of agility our industry needs to outpace clinical timelines and deliver life-changing therapies. We look forward to sharing data as our TransBioTech studies progress and showcasing how each preclinical milestone parallels growth in shareholder value. Thank you for your continued trust as we pioneer the Satoshi Trials™ model, fighting ALS and other complex diseases by marrying biotech rigor with Bitcoin’s financial power. We look forward to sharing our success on this journey and the results of the research as we continue from here. Onward with focus and intention, _Akeem Gardner | CEO & Founder | Canurta Therapeutics_ --- *Originally published on [Canurta.eth](https://paragraph.com/@canurta/satoshi-trials-in-action)*